Pharmacia Could See Double COX-2 NME Drug Approvals In 2001
Executive Summary
Pharmacia could gain approval of two COX-2 inhibitor drugs that are new molecular entities by late 2001.
You may also be interested in...
FDA Drug Approval Time Edges Up To 18.5 Months In 2001
The average NDA approval time is still about a year and a half, an analysis of new molecular entities cleared by FDA in 2001 shows
FDA Drug Approval Time Edges Up To 18.5 Months In 2001
The average NDA approval time is still about a year and a half, an analysis of new molecular entities cleared by FDA in 2001 shows
Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.